venBio Partners LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO

venBio Partners LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,884,638 shares of the company’s stock, valued at approximately $26,671,201,000. ALX Oncology accounts for about 5.1% of venBio Partners LLC’s holdings, making the stock its 5th biggest position. venBio Partners LLC owned about 0.09% of ALX Oncology as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Callan Family Office LLC acquired a new position in shares of ALX Oncology during the 2nd quarter valued at $46,000. The Manufacturers Life Insurance Company acquired a new stake in ALX Oncology in the second quarter worth $64,000. Bridgeway Capital Management LLC bought a new stake in ALX Oncology in the third quarter valued at $66,000. Invesco Ltd. bought a new stake in ALX Oncology in the first quarter valued at $46,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of ALX Oncology during the first quarter valued at about $150,000. Institutional investors own 97.97% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ALXO shares. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.60.

ALX Oncology Trading Up 3.5%

NASDAQ ALXO opened at $2.05 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.71 and a quick ratio of 9.71. The stock has a market capitalization of $283.47 million, a price-to-earnings ratio of -1.81 and a beta of 0.42. ALX Oncology Holdings Inc. has a one year low of $0.96 and a one year high of $2.66. The business’s fifty day moving average is $2.00 and its 200-day moving average is $1.97.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. Equities research analysts predict that ALX Oncology Holdings Inc. will post -0.6 EPS for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.